Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company's new scientific advisory board. Joining Cunningham on Prosonix's SAB are: Peter Barnes, Professor of Thoracic Medicine and Head of Airway Disease, National Heart and Lung Institute, and Honorary Consultant Physician, Royal Brompton … [Read more...] about New scientific advisory board for Prosonix
Business
Acton Pharmaceuticals will develop and market Nasacort HFA in US
Massachusetts respiratory pharmaceutical company Acton Pharmaceuticals has entered into a licensing agreement with Sanofi US that gives Acton exclusive US rights to develop and market prescription Nasacort HFA triamcinolone acetonide nasal aerosol for the treatment of nasal allergy symptoms due to seasonal or perennial rhinitis in adults and children 6 years old and … [Read more...] about Acton Pharmaceuticals will develop and market Nasacort HFA in US
Impel gets new funding for development of intranasal delivery
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of equity investment from "angel investors experienced in the pharmaceutical and medical device industries," it has also entered into collaborations with … [Read more...] about Impel gets new funding for development of intranasal delivery
Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other's technologies. The partnership also gives Bend access to Hovione's commercial manufacturing capabilities in Portugal, Ireland, China, and the US. “Hovione has world-class … [Read more...] about Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Insight recalls lot of Nostrilla nasal decongestant spray
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092 1/2-oz bottles, was distributed in US retail stores and pharmacies. According to Insight, it has … [Read more...] about Insight recalls lot of Nostrilla nasal decongestant spray
Perrigo files an ANDA for a generic Patanase nasal spray; Alcon files suit
According to Perrigo, Alcon Labs has filed a patent infringement suit in the United States District Court for the Northern District of Texas after Perrigo filed an abbreviated new drug application (ANDA) for a generic version of Alcon's Patanase olopatadine hydrochloride nasal spray. The FDA approved Alcon's NDA for Patanase for the treatment of seasonal allergic … [Read more...] about Perrigo files an ANDA for a generic Patanase nasal spray; Alcon files suit
Some acetylcysteine inhalation solution now available
According to the FDA, American Regent/Luitpold has now released several batches of acetylcysteine inhalation solution, including 10 ml vials of both 100 mg/ml and 200 mg/ml solutions and 30 ml vials of the 200 mg/ml solution. The company's facility in Shirley, NY was closed in April 2011 due to safety concerns. Two other manufacturers, Roxanne Laboratories and … [Read more...] about Some acetylcysteine inhalation solution now available
Fentanyl nasal spray now available in the US
Archimedes Pharma has officially launched its Lazanda fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients in the United States. Lazanda, the first fentanyl nasal spray available in the US, was approved by the FDA at the end of June 2011. In Europe, where the product is marketed as PecFent, the spray is available in a handful of … [Read more...] about Fentanyl nasal spray now available in the US
Azelon gets financing for osteoporosis nasal spray, adds to management team
Prospect Venture Partners, Lighthouse Capital Partners, and Covington Venture Fund will provide a total of $4.5 million in Series A financing to Azelon Pharmaceuticals, formerly Zelos Therapeutics, for continued clinical development of Azelon’s ZT-034 teriparatide nasal spray for the treatment of osteoporosis. Teriparatide is a parathyroid hormone analog and is … [Read more...] about Azelon gets financing for osteoporosis nasal spray, adds to management team
Teva UK launches generic HFA salmeterol MDI
Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for the Neovent/Sereflo inhaler for the treatment of asthma and COPD to Neolab Limited in April 2011. Kim Innes, Teva UK Commercial Director, commented, "We are … [Read more...] about Teva UK launches generic HFA salmeterol MDI